靶向蛋白S的小干扰核糖核酸增强血友病止血效力
研究评估抑制蛋白S(PS)能否增加血友病A(HA)和B(HB)患者血浆的凝血酶生成(TG),并开发了N-乙酰半乳糖胺偶联的肝细胞靶向PS小干扰RNA(siRNA)。多克隆抗体抑制PS使HA血浆TG增加3–5倍、HB增加4–9倍,血浆PS降低70%;临床前模型中皮下PS-siRNA降低PS水平、改善血凝并预防出血,且未引发广泛血栓形成。
要点
- 多克隆抗体抑制PS使HA血浆TG增加3–5倍、HB增加4–9倍,血浆PS降低70%。
- 皮下PS-siRNA在HA小鼠和非人灵长类中降低PS水平并改善血凝。
- PS-siRNA在HA小鼠隐静脉穿刺和膝关节损伤模型中预防出血,未触发广泛血栓形成。
核心结论
- 降低PS水平可增强血友病模型中的TG,PS-siRNA疗法在改善止血方面显示出前景,值得进一步临床研究作为血友病的潜在治疗。
研究设计与样本
- 研究评估HA和HB患者血浆的TG,并开发N-乙酰半乳糖胺偶联的肝细胞靶向PS-siRNA,同时在临床前模型中评估其治疗潜力。
主要发现
- 多克隆抗体抑制PS使HA血浆TG增加3–5倍、HB血浆TG增加4–9倍,同时血浆PS降低70%。
- 在临床前模型中,皮下PS-siRNA疗法在HA小鼠和非人灵长类中成功降低PS水平并改善血凝形成。
- PS-siRNA在HA小鼠隐静脉穿刺和膝关节损伤模型中预防出血。
- PS-siRNA增强凝血而未触发广泛血栓形成。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出该疗法值得进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One hemophilia treatment concept focuses on rebalancing coagulation and anticoagulation to restore normal blood clotting. Targeting the coagulation regulator, protein S (PS), in hemophilia shows promise to increase the generation of thrombin, a critical enzyme in the clotting process. OBJECTIVES: This study aimed to: (1) assess whether inhibiting PS increases thrombin generation (TG) in plasma from individuals with hemophilia A (HA) and B (HB); and (2) develop a hepatocyte-targeted PS small interfering RNA (siRNA) therapy using N-acetylgalactosamine conjugation to restore hemostasis in hemophilia without increasing thromboembolic risks. METHODS: We assessed TG in plasma from patients with HA and HB. To target the liver specifically, we developed a PS-siRNA conjugated with N-acetylgalactosamine. This approach ensures that PS levels remain adequate in other cells, thereby minimizing the risk of thrombosis. Additionally, we evaluated the therapeutic potential of PS-siRNA in preclinical models. RESULTS: Inhibiting PS with a polyclonal antibody in plasma resulted in a 3- to 5-fold increase in TG in HA and a 4- to 9-fold increase in HB plasma, with a 70% reduction in plasma PS. In preclinical models, subcutaneous PS-siRNA therapy in HA mice and nonhuman primates successfully lowered PS levels and improved clot formation. It also prevented bleeding in both saphenous vein puncture and knee injury models in HA mice. Notably, it enhanced clotting without triggering widespread clot formation. CONCLUSION: Reducing PS levels enhances TG in hemophilia models, and PS-siRNA therapy shows promise in improving hemostasis. This approach warrants further clinical investigation as a potential treatment for hemophilia.
引用
- Eladnani RP, Schaeper U, Diab R, et al. Enhancing hemostasis potency in hemophilia with a small interfering ribonucleic acid targeting protein S. J Thromb Haemost. 2025. PMID: 40154791. doi:10.1016/j.jtha.2025.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。